Article Text

Download PDFPDF

5PSQ-221 Safety profile of experimental therapies used in the COVID-19 pandemic based on data from the National Minimum Data Set
  1. I Oterino Moreira1,
  2. S Sanz Marquez1,
  3. L Carrasco Piernavieja1,
  4. E Zhan Zhou1,
  5. JJ Martinez Simón1,
  6. I Salvador Llana1,
  7. S Lorenzo Martínez2,
  8. MDC Morales Catalan2,
  9. I Plo Seco1,
  10. P Roldan Navarro1,
  11. M Pérez Encinas1
  1. 1Hospital Universitario Fundacion Alcorcon, Hospital Pharmacist, Alcorcon, Spain
  2. 2Hospital Universitario Fundacion Alcorcon, Quality Assurance, Alcorcon, Spain


Background and importance In response to the COVID-19 pandemic, scientific societies and regulatory agencies quickly reviewed any available evidence to fill the therapeutic gap. In this context, many drugs were used with an uncertain benefit–risk profile that needs to be evaluated.

Aim and objectives To analyse the safety profile of experimental therapies that were used at the beginning of the COVID-19 pandemic.

Material and methods A retrospective observational study was conducted to analyse the safety profile of anti-COVID therapy accessible according to the protocols that were approved. Patients admitted with a COVID-19 diagnosis between March and May 2020 who had an adverse event (AE) coded in the discharge/death medical report were obtained from the National Minimum Data Set. The suspected drug was identified based on previous information. Those with AEs attributed to anti-COVID therapy were selected. The causal relationship was evaluated using Naranjo’s algorithm (NA).

Results 141 AEs were coded in 105 patients admitted with a diagnosis of COVID-19. 60.3% were attributed to anti-COVID therapy in 66 patients with a median age of 72 years (95% CI 68 to 76), 62.1% men (37.9% women). AE severity was: 63.5% mild, 29.4% moderate and 7.1% severe. 23.5% of AEs did not require intervention, 37.6% required pharmacological treatment, 35.3% suspension of the drug, 2.4% close monitoring and 1.2% dose reduction.

Abstract 5PSQ-221 Table 1

Conclusion and relevance NA established a probable drug–AE causal relationship for most events. Most AEs were moderate to mild in severity but 75% required medical intervention. Consequently, it is important to know the AE–drug relationship to ensure a favourable benefit–risk profile, especially for experimental therapies.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.